Global Immunotherapy Market 2025-2035

Description

List of Tables

Immunotherapy Market Size, Share & Trends Analysis Report by Type (Monoclonal Antibodies, Cancer Vaccines, Autoimmune Checkpoint Inhibitors, Interleukins and Interferons (Cytokines), and Others) by Application (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others) and by End User (Hospitals, Diagnostic Centers, and Others) Forecast Period (2025-2035)

Industry Overview

Immunotherapy market was valued at $216.5 billion in 2024 and is projected to reach $710.3 billion by 2035, growing at a CAGR of 11.5% during the forecast period (2025-2035). The market growth is driven by the rising global incidence of cancers and other chronic diseases, advancements in personalized and targeted therapies, and increased research and development funding. Other factors include the development of new therapies such as CAR T-cell therapy and immune checkpoint inhibitors, favorable regulatory policies, greater patient awareness, and the increasing use of combination therapies to improve outcomes.

Market Dynamics

Rising Cancer Incidence and Demand for Effective Treatments

The increasing prevalence of cancer globally is a primary driver of the immunotherapy market. With an estimated 2 million new cancer cases and over 600,000 cancer-related deaths in the U.S. alone in 2024, the demand for innovative and effective treatments is escalating. This surge in cancer cases is prompting healthcare systems to seek advanced therapies, positioning immunotherapy as a critical component of modern oncology.

Technological Advancements and Personalized Medicine

Advancements in genomics, biotechnology, and artificial intelligence are revolutionizing immunotherapy. These technologies enable the development of more targeted and personalized treatments, enhancing the efficacy and safety profiles of therapies. The ability to tailor treatments to individual genetic profiles is expanding the applicability of immunotherapy across various cancer types.

Regulatory Approvals and Market Expansion

The increasing number of regulatory approvals for novel immunotherapies is facilitating market growth. As more therapies receive approval from agencies like the FDA and EMA, the availability of treatment options expands, fostering competition and innovation within the market.

Market Segmentation

Based on the type, the market is segmented into monoclonal antibodies, cancer vaccines, autoimmune checkpoint inhibitors, interleukins and interferons (cytokines), and others.
Based on the application, the market is segmented into cancer, autoimmune and inflammatory diseases, infectious diseases, and others.
Based on the end user, the market is segmented into hospitals, diagnostic centers, and others.

Monoclonal Antibodies Segment Led to the Largest Segment

The monoclonal antibodies (mAbs) segment has established itself as the dominant force in the global immunotherapy market. In 2024, mAbs accounted for a substantial 64.97% of the cancer immunotherapy market share. This dominance is attributed to their high specificity and efficacy in targeting cancer cells, leading to improved patient outcomes. Notably, pembrolizumab (Keytruda), a PD-1 inhibitor, emerged as the top-selling immunotherapy drug in 2024, generating $29.5 billion in sales. The widespread adoption of mAbs, bolstered by regulatory approvals and clinical success, underscores their pivotal role in the immunotherapy landscape.

Cancer: A Key Segment in Market Growth

Among the various applications of immunotherapy, cancer dominates the market, accounting for the largest share globally. The rising prevalence of cancer globally, coupled with the limitations of conventional therapies such as chemotherapy and radiation, has significantly fueled the adoption of immunotherapy. Monoclonal antibodies, checkpoint inhibitors, and CAR-T therapies are increasingly used to target specific cancer cells with higher precision and fewer side effects. Oncology applications continue to receive substantial R&D investments, with ongoing clinical trials expanding the scope of treatable cancer types. This focus on oncology has not only increased patient survival rates but also strengthened the market position of cancer-focused immunotherapies as the primary revenue-generating segment.

Regional Outlook

The global immunotherapy industry is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Maintains Strong Market Position

In North America, the US dominates the global immunotherapy market, holding the largest share due to its advanced healthcare infrastructure, significant investments in research and development, and a high prevalence of cancer and autoimmune diseases. In 2024, North America accounted for approximately 43.88% of the global cancer immunotherapy market share, with the US being the primary contributor. The country's well-established healthcare system, robust pharmaceutical industry, and favorable regulatory environment have facilitated the rapid development and adoption of immunotherapy treatments. Additionally, the US. Government's support for biomedical research and the presence of leading biotech companies have accelerated the availability of innovative therapies. This dominance is further reinforced by the nation's proactive approach to clinical trials, regulatory approvals, and healthcare policy, positioning the US at the forefront of the global immunotherapy market.

Market Players Outlook

The major companies operating in the global immunotherapy market include AbbVie, Bristol-Myers Squibb (BMS), F. Hoffmann-La Roche Ltd., Merck & Co., Novartis AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In October 2025, the FDA approved cemiplimab as the first and only adjuvant immunotherapy for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. The therapy significantly extends disease-free survival (DFS) compared to placebo, with a 68% lower risk of disease recurrence or death. The C-POST trial included 415 patients at high risk of recurrence due to extracapsular extension or multiple lymph nodes affected. The median duration of treatment was 47.9 weeks for cemiplimab and 64.1% for placebo. The most common adverse events with cemiplimab were fatigue, pruritus, rash, and diarrhea. The therapy is also approved to treat basal cell carcinoma and non-small cell lung cancer in combination with chemotherapy or alone in tumors without EGFR, ALK, or ROS1 mutations.
In August 2025, Intas Pharmaceuticals launched HETRONIFLY (Serplulimab), the first PD-1 inhibitor globally approved for treating Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in India. The drug, which is currently approved in over 40 countries, has been approved in the ASTRUM-005 trial, which showed a 40% reduction in death risk and a higher overall survival rate compared to current chemotherapy. Its unique dual-blockade mechanism and high PD-1 internalization set it apart in deep immune engagement for solid tumors. The drug is priced 75% lower than existing immunotherapies.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global immunotherapy market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2024014

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Immunotherapy Market Sales Analysis - Type | Application | End-User ($ Million)
Immunotherapy Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Immunotherapy Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Immunotherapy Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Immunotherapy Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Immunotherapy Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Immunotherapy Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Immunotherapy Market Revenue and Share by Manufacturers
Immunotherapy Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. AbbVie
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Bristol-Myers Squibb (BMS)
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. F. Hoffmann-La Roche Ltd.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Merck & Co.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Novartis AG
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Immunotherapy Market Sales Analysis by Type ($ Million)

5.1. Monoclonal Antibodies
5.2. Cancer Vaccines
5.3. Autoimmune Checkpoint Inhibitors
5.4. Interleukins and Interferons (Cytokines)
5.5. Others

6. Global Immunotherapy Market Sales Analysis by Application ($ Million)

6.1. Cancer
6.2. Autoimmune and Inflammatory Diseases
6.3. Infectious Diseases
6.4. Other Application

7. Global Immunotherapy Market Sales Analysis by End-User ($ Million)

7.1. Hospitals
7.2. Diagnostic Centers
7.3. Others

8. Regional Analysis

8.1. North American Immunotherapy Market Sales Analysis - Type | Application | End-User ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Immunotherapy Market Sales Analysis - Type | Application | End-User ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Immunotherapy Market Sales Analysis - Type | Application | End-User ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Immunotherapy Market Sales Analysis - Type | Application | End-User ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. AbbVie
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Amgen
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. AstraZeneca
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Bayer AG
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Biogen
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. Bristol-Myers Squibb
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Eli Lilly and Co.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Genmab A/S
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. GSK
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. Johnson & Johnson
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. Merck & Co.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Mylan N.V.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Novartis
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Pfizer
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. Regeneron Pharmaceuticals
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Roche
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Sanofi
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Sun Pharmaceutical Industries
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Takeda
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. UCB Pharma
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies